Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Six-Month, Open-Label, Re-Treatment Study of Probuphine in Opioid Addiction

NCT01262261 is registered in ClinicalTrials.gov with Titan Pharmaceuticals as lead sponsor.

NCT NCT01262261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01262261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Six-Month, Open-Label, Re-Treatment Study of Probuphine in Opioid Addiction
Lead sponsor
Titan Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2010
Completion date
November 30, 2011
Enrollment
85 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

opioid dependency